- Home
- RXRX vs ELVN Comparison
RXRX vs ELVN Comparison
Compare RXRX & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RXRX | ELVN |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RXRX | ELVN |
|---|---|---|
| Price | $3.00 | $52.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $7.50 | ★ $43.40 |
| AVG Volume (30 Days) | ★ 23.4M | 1.3M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.79 | 3.17 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $74,681,000.00 | N/A |
| Revenue This Year | $12.11 | N/A |
| Revenue Next Year | $82.52 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 26.92 | N/A |
| 52 Week Low | $2.77 | $14.79 |
| 52 Week High | $7.18 | $54.88 |
Technical Indicators
Market Signals| Indicator | RXRX | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 38.34 | 60.00 |
| Support Level | $2.88 | $25.63 |
| Resistance Level | $4.03 | N/A |
| Average True Range (ATR) | 0.20 | 2.36 |
| MACD | -0.08 | -0.15 |
| Stochastic Oscillator | 8.80 | 70.20 |
Price Performance
Historical ComparisonAbout RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.